Home / Patients Family / Academy / Digital Academy

Digital Academy

 

MDF community members living with DM and their caregivers present on current symptom management strategies for living with DM, and what they would like to see in clinically-meaningful therapies. Dr. Jonathan Goldsmith, M.D., FACP, head of the Office of Rare Diseases at the FDA, provided a summary of the proceedings and what the FDA took away from the patient input shared at this meeting – at the 2016 DM Patient-Focused Drug Development meeting, a component of the 2016 MDF Annual Conference.

 

MDF community members living with DM, and their caregivers present on the impacts of DM on daily living, in response to specific questions posed by the Food and Drug Administration, which is in charge of reviewing and approving therapies in the U.S. Dr. Janet Woodcock, M.D., who leads all drug evaluation and research at the FDA, also provided remarks – at the 2016 DM Patient-Focused Drug Development meeting, a component of the 2016 MDF Annual Conference.

Representatives from various biotech and pharmaceutical companies around the world discuss early stage therapies currently under development. Featuring Dr. Friedrich Metzger, PhD, Head of Discover in Rare Diseases at Roche; Dr. Takako Moriguchi, PhD, Senior Scientist at Genzyme; and Michael French, Chief Executive Officer at Marina Biotech.

Dr. Laurence Mignon, PhD, Director of Clinical Development at Isis Pharmaceuticals, gives an update on the status of the DMPKrx Phase I/II trial.

Dr. Sharon Hesterlee, PhD, Chief Science Officer at MDF, discusses the Foundation's multi-year vision to accelerate DM research.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.